Immunovaccine Appoints Marc Mansour as Chief Executive Officer

Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company") (TSX
VENTURE:IMV), a clinical stage vaccine and immunotherapy company, today
announced that Marc Mansour, Ph.D., MBA, has been appointed Chief Executive
Officer. Albert Scardino, executive chairman since last year, will return to his
role as non-executive chairman of the Company. Dr. Mansour has previously served
as the Company's Chief Operating Officer and Chief Science Officer and is a
member of its board of directors. 


Since joining Immunovaccine in 2001, Dr. Mansour has led the development of
Immunovaccine's DepoVax(TM) platform and the Company's lead therapeutic cancer
vaccine DPX-Survivac, which is being prepared for multiple Phase II clinical
studies in 2014. During his recent tenure as COO, Dr. Mansour also spearheaded
interactions with the investment community, as well as business development
efforts.


Albert Scardino, chairman of Immunovaccine, commented,

"During his 13 years at Immunovaccine, Marc has contributed to all aspects of
our development, from cutting-edge scientific research to day-to-day corporate
operations. No individual has a better understanding of where Immunovaccine has
been or what it will take to advance the Company to the next phase of its
evolution."


Immunovaccine earlier this month presented positive results from a Phase I/Ib
clinical study of DPX-Survivac at the American Society of Clinical Oncology
(ASCO) 2014 Annual Meeting, demonstrating the first evidence of clinical
activity for the cancer vaccine. 


While the majority of ovarian cancer patients enrolled in the study were
complete responders to their previous therapy and presented no evidence of
disease at the time of enrollment, three patients entered the Phase Ib study
with stable disease. One of those three patients experienced a partial response
(PR) as measured by Response Evaluation Criteria In Solid Tumors (RECIST 1.1),
while the other two experienced disease progression. The responding patient
achieved a 43% reduction in tumor size, as well as reduction in levels of a
commonly used ovarian cancer biomarker (CA125) and a significant increase in
vaccine-induced immune responses. The patient's tumor and CA125 levels remain
stable eight months following initiation of the DPX-Survivac therapy,
demonstrating a potentially durable effect of the therapy. 


"This is an exciting time for Immunovaccine and the broader cancer immunotherapy
field. Our announcement of the DPX-Survivac data at the annual ASCO conference
has resulted in a significant amount of interest from key opinion leaders for
further investigation of the cancer vaccine. As a direct result of this KOL
interest, we are exploring two additional Phase II clinical studies of
DPX-Survivac in ovarian cancer and lymphoma potentially in 2014," stated Dr.
Mansour. 


As previously announced, a large randomized Phase II trial of DPX-Survivac in
ovarian cancer will be sponsored and conducted by Canada's NCIC Clinical Trials
Group (NCIC CTG). The NCIC CTG is expected to initiate the 250 patient trial in
2014. 


About Immunovaccine 

Immunovaccine Inc. develops cancer immunotherapies and infectious disease
vaccines based on the Company's DepoVax(TM) platform, a patented formulation
that provides controlled and prolonged exposure of antigens and adjuvant to the
immune system. Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine therapy,
DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian
cancer and glioblastoma (brain cancer). The Company is also advancing an
infectious disease pipeline including innovative vaccines for respiratory
syncytial virus (RSV) and anthrax.  


Connect at www.imvaccine.com

This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future, including information regarding the use of
proceeds of the financing, is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release except
as required by law. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine Inc.
Dr. Marc Mansour
Chief Executive Officer
(902) 492-1819
mmansour@imvaccine.com
www.imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
tbrons@vidasp.com
(TSXV:IMV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024